King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Sabah Alaklabi
Dr. Sabah Alaklabi is a Consultant Medical Oncologist specialising in breast cancer, and a leading breast cancer specialist in Riyadh, Saudi Arabia. Her practice combines evidence-based systemic therapy with translational research on metastatic and triple-negative breast cancer.
- Lead author on the Saudi national consensus for management of early and metastatic breast cancer
- International research collaborations with Roswell Park Comprehensive Cancer Center, USA
- Published real-world outcomes of Sacituzumab Govitecan in metastatic breast cancer
- Expertise in neighborhood deprivation index research and breast cancer survival disparities
- Breast Cancer Centre faculty at a Cancer Centre of Excellence in Riyadh
Qualifications & Credentials
Medical Degrees
- MBBS — Information not publicly available.
- Medical Oncology Specialty Training — Information not publicly available.
Fellowships & Special Training
- Research Fellowship / Oncology Training — Roswell Park Comprehensive Cancer Center, Buffalo, USA
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) registration
- Information not publicly available.
Areas of Expertise
Major Conditions Treated
- Early-Stage Breast Cancer (ER+, PR+, HER2+, Triple-Negative)
- Metastatic Breast Cancer
- HER2-Low Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Luminal A and Luminal B Breast Cancer
- BRCA-Associated Breast Cancer
Sub-specialties
- Metastatic Breast Cancer: Expert in advanced systemic therapy including antibody-drug conjugates (Sacituzumab Govitecan), CDK 4/6 inhibitors, and targeted therapies — a key offering for international patients seeking best breast cancer treatment in Saudi Arabia.
- Triple-Negative Breast Cancer (TNBC): Leading contributor to translational research on TNBC, including real-world outcome analysis and novel therapy trials.
- Neoadjuvant & Adjuvant Chemotherapy: Tailored protocols integrating immunotherapy, anthracycline, and taxane-based regimens.
Advanced Procedures & Treatments
- Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
- Adjuvant Systemic Therapy (chemotherapy, endocrine, targeted)
- Antibody-Drug Conjugate Therapy (Sacituzumab Govitecan, Trastuzumab Deruxtecan)
- HER2-Targeted Therapy (Trastuzumab, Pertuzumab, T-DXd)
- CDK 4/6 Inhibitor Therapy
- Immune Checkpoint Inhibitor Therapy for TNBC
- Endocrine Therapy (Tamoxifen, Aromatase Inhibitors, Fulvestrant)
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (Cancer Centre of Excellence), Riyadh, Saudi Arabia — Consultant, Breast Cancer Centre, Medical Oncology Department (Current)
Past Affiliations
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA — Research Fellowship / Oncology Training
Academic & Research Roles
- Principal investigator — Saudi Delphi consensus on early and metastatic breast cancer management
- Co-investigator — International collaborative studies with Roswell Park Comprehensive Cancer Center
Key Achievements
- Co-developed Saudi Arabia's 2025 Consensus Statement on Management of Early and Metastatic Breast Cancer
- Lead author on single-institution real-world outcomes of Sacituzumab Govitecan in mTNBC
- Active contributor to GCC-region breast cancer research and clinical guideline development
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO) — Information not publicly available.
- European Society for Medical Oncology (ESMO) — Information not publicly available.
- Saudi Oncology Society
Research & Publications
Published Papers (Selected)
- Alaklabi S, Akhtar S, AL-Tweigeri T et al. Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia. Oncol Ther. 2025. DOI: 10.1007/s40487-025-00404-9
- Alaklabi S, Elijah J, Roy AM, Groman A, Gandhi S. Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience. CancerNetwork. 2023.
- Roy AM, Jiang C, Yao S, Perimbeti S, Attwood K, Alaklabi S, Patel A, Omilian AR, Gandhi S. Effect of neighborhood deprivation index on breast cancer survival in the United States. 2023 (PMC10504126).
Ongoing Research & Clinical Interests
- Metastatic triple-negative breast cancer (mTNBC)
- Antibody-drug conjugates and HER2-low biology
- Disparities in breast cancer outcomes
- Real-world evidence in oncology
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | SAR 500 – SAR 1,500 | $135 – $400 |
| Chemotherapy Cycle (regimen-dependent) | SAR 15,000 – SAR 70,000 | $4,000 – $18,700 |
| Targeted Therapy (per month, HER2 / CDK 4-6) | SAR 30,000 – SAR 90,000 | $8,000 – $24,000 |
| Antibody-Drug Conjugate Therapy (per cycle) | SAR 40,000 – SAR 120,000 | $10,700 – $32,000 |
| Immunotherapy (per cycle) | SAR 30,000 – SAR 80,000 | $8,000 – $21,300 |
Frequently Asked Questions
1. What advanced technologies does Dr. Sabah Alaklabi use as a Medical Oncologist?
Dr. Sabah Alaklabi uses state-of-the-art breast cancer treatments including antibody-drug conjugates (Sacituzumab Govitecan, Trastuzumab Deruxtecan), CDK 4/6 inhibitors, immune checkpoint inhibitors for TNBC, and molecular profiling-guided therapy. International virtual second opinions can be arranged via Cancer Rounds.
2. What conditions does Dr. Sabah Alaklabi specialize in treating?
Dr. Sabah Alaklabi treats the full spectrum of breast cancer — early-stage, locally advanced, and metastatic disease, including triple-negative breast cancer, HER2-positive and HER2-low subtypes, hormone receptor-positive disease, and BRCA-related breast cancer. She is a recognised breast cancer medical oncologist in Riyadh for complex and refractory cases.
3. How do I book an appointment with Dr. Sabah Alaklabi?
Appointments with Dr. Sabah Alaklabi can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Sabah Alaklabi?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Sabah Alaklabi, including Saudi Arabia medical visa invitation letters, airport transfers, and local accommodation coordination in Riyadh.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation (Arabic, English, and more), financial counselling, and pre-travel virtual consultations to review medical records before arrival in Riyadh.
6. Does Dr. Sabah Alaklabi offer second opinions as a Medical Oncologist?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with Dr. Sabah Alaklabi, an expert Medical Oncologist in Riyadh, Saudi Arabia.
